Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis


You May Also Like

Global Orphan Drug Pipeline & Regulatory Insight Report 2018

Dublin, Sept. 11, 2018 (GLOBE NEWSWIRE) -- The "Global Orphan Drug Pipeline & Regulatory ...

INSYS Therapeutics Reports Third Quarter 2018 Results

Company’s Position as a Leader and Strategic Partner in Pharmaceutical Cannabinoids Strengthens with Involvement ...